BAYESIAN HIERARCHICAL MODELING FOR DETECTING SAFETY SIGNALS IN CLINICAL TRIALS

被引:47
作者
Xia, H. Amy [1 ]
Ma, Haijun [1 ]
Carlin, Bradley P. [2 ]
机构
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Univ Minnesota, St Paul, MN USA
关键词
Bayesian hierarchical models; Clinical trials; Drug safety; Multiplicity; Signal detection; FALSE DISCOVERY RATE; DRUG;
D O I
10.1080/10543406.2010.520181
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Detection of safety signals from clinical trial adverse event data is critical in drug development, but carries a challenging statistical multiplicity problem. Bayesian hierarchical mixture modeling is appealing for its ability to borrow strength across subgroups in the data, as well as moderate extreme findings most likely due merely to chance. We implement such a model for subject incidence (Berry and Berry, 2004) using a binomial likelihood, and extend it to subject-year adjusted incidence rate estimation under a Poisson likelihood. We use simulation to choose a signal detection threshold, and illustrate some effective graphics for displaying the flagged signals.
引用
收藏
页码:1006 / 1029
页数:24
相关论文
共 20 条
  • [1] A Bayesian neural network method for adverse drug reaction signal generation
    Bate, A
    Lindquist, M
    Edwards, IR
    Olsson, S
    Orre, R
    Lansner, A
    De Freitas, RM
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (04) : 315 - 321
  • [2] ON THE CONSEQUENCES OF MODEL MISSPECIFICATION IN LOGISTIC-REGRESSION
    BEGG, MD
    LAGAKOS, S
    [J]. ENVIRONMENTAL HEALTH PERSPECTIVES, 1990, 87 : 69 - 75
  • [3] Benjamini Y, 2001, ANN STAT, V29, P1165
  • [4] CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING
    BENJAMINI, Y
    HOCHBERG, Y
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) : 289 - 300
  • [5] Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488
  • [6] Accounting for multiplicities in assessing drug safety: A three-level hierarchical mixture model
    Berry, SM
    Berry, DA
    [J]. BIOMETRICS, 2004, 60 (02) : 418 - 426
  • [7] ON FOUNDATIONS OF STATISTICAL-INFERENCE
    BIRNBAUM, A
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1962, 57 (298) : 269 - &
  • [8] Carlin BP., 2008, Bayesian methods for data analysis
  • [9] CHI G, 2002, PHARM REPORT, V9, P1
  • [10] Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team
    Crowe, Brenda J.
    Xia, H. Amy
    Berlin, Jesse A.
    Watson, Douglas J.
    Shi, Hongliang
    Lin, Stephen L.
    Kuebler, Juergen
    Schriver, Robert C.
    Santanello, Nancy C.
    Rochester, George
    Porter, Jane B.
    Oster, Manfred
    Mehrotra, Devan V.
    Li, Zhengqing
    King, Eileen C.
    Harpur, Ernest S.
    Hall, David B.
    [J]. CLINICAL TRIALS, 2009, 6 (05) : 430 - 440